Baidu
map

LANCET HEALTHY LONGEVITY:平时多锻炼,伤后预后好

2022-08-31 影像小生 MedSci原创

该研究结果支持将CFS纳入创伤路径,以帮助患者管理。此外,定期锻炼的人(CFS为1-2)比活动水平较低的人(CFS≥3)有更好的预后,支持将锻炼作为改善创伤预后的干预措施。

严重受伤占全世界死亡人数的1 / 12,老年人因这类伤害而死亡的风险最大。摔倒造成的伤害是老年人最常见的伤害机制,每年造成60多万人死亡,其中四分之三发生在低收入和中等收入国家。随着全球人口继续老龄化,老年人遭受创伤的比例将增加。2014年,英国因创伤入院的患者中有一半年龄在60岁以上。2015年,美国有三分之一的受伤患者年龄在65岁及以上。

创伤护理正开始适应这一不断变化的患者群体。从历史上看,老年伤者特有的临床特征,如认知障碍或生理反应减弱,导致对病理学的认识不足,并导致现场分诊并送往专门中心的可能性降低许多因素改变老年人受伤后的恢复能力,而年龄传统上被用作预后不良的预测因素;然而,老年是一种异质性的状态。年龄本身并不能描述一个人内在的健康状况或生理恢复能力。衰弱描述的是一种生理和认知储备减少的状态,尽管与年龄有关,但在老年人中并不普遍。衰弱决定了一个人应对应激事件的能力,如急性疾病、手术或创伤。因此,衰弱可以用来识别有不良结果风险的人,这样他们就可以被纳入与衰弱协调的护理途径,这样做可能会为以人为中心的决策讨论提供早期信息。

老年人是因重伤入院的最大群体。许多老年人身体衰弱,这是恢复不良的一个风险因素。英国布里斯托尔Southmead医院Ben Carter等研究了受伤前衰弱对预后的影响。研究结果发表在LANCET HEALTHY LONGEVITY

在这项多中心观察研究(FiTR 1)中,研究小组从创伤审计与研究网络(TARN)数据库中提取了前瞻性收集的数据,这些数据来自英国所有23个成人主要创伤中心,在2.5年的时间内收治了严重受伤的老年人(年龄≥65)。老年医学专家评估了损伤前临床衰弱量表(Clinical Frailty Scale, CFS),这是一个9分制的健康和虚弱量表,1分表示患者非常健康,9分表示患者处于绝症状态。主要转归为住院死亡率,患者出院时接受审查。使用拟合调整风险比(aHRs)的多水平Cox回归模型来评估CFS和死亡率之间的关联,CFS评分按以下方式分组:1-2分表明患者适合;3例患者表现良好;4 - 8分表明患者生活衰弱(4为非常轻,5为轻,6为中度,7-8为严重)

2019331日至20211031日期间,TARN持有193156例患者的记录,其中16504例有合格记录。中位年龄81.9(IQR 74·7-88·0),女性9200(55·7%),男性7304(44·3%)。在CFS评分为1-816438例患者中,11114(67.6%)生活衰弱(CFS评分为4-8)1660(10.1%)患者在住院期间死亡,从入院到死亡的中位时间为9(IQR 4-18)

从入院到死亡期间的Kaplan-Meier生存函数,按损伤前CFS进行分层

 表2.受伤前衰弱程度与住院患者死亡率相关系

 

3.受伤前衰弱程度与住院时间相关性

CFS评分为1-2的患者相比,管理良好的患者 (CFS评分为3;aHR1·82 [95% CI1·39 ~ 2·40])、极轻衰弱生活(CFS评分为4:1·99[1·51 ~ 2·62])、轻度衰弱生活(CFS评分为5:2·61[1·99 ~ 3·43])、中度衰弱生活(CFS评分为6:2·97[2·26 ~ 3·90])、重度衰弱生活(CFS评分为7 ~ 8:4·03[3·04 ~ 4·34]) 的住院死亡风险增加。

总之,这项多中心的国家研究提供了证据,证明衰弱生活对老年人重伤后住院死亡率的影响。这些数据支持在受伤后不久纳入衰弱评估,而不是年龄,以在临床路径中对患者进行适当的分诊并预测结果。这些数据将支持在临床实践中尽早使用衰弱评估来进行适当的分诊护理

原文出处

A national study of 23 major trauma centres to investigate the effect of frailty on clinical outcomes in older people admitted with serious injury in England (FiTR 1): a multicentre observational study

https://doi.org/10.1016/S2666-7568(22)00122-2

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1861513, encodeId=b6ab186151330, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Jan 17 14:55:59 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831645, encodeId=97b4183164555, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Oct 16 19:55:59 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621961, encodeId=2c5c162196141, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Sep 01 11:55:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244087, encodeId=166f124408e27, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Tue Aug 30 23:55:59 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2023-01-17 shizhenshan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1861513, encodeId=b6ab186151330, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Jan 17 14:55:59 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831645, encodeId=97b4183164555, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Oct 16 19:55:59 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621961, encodeId=2c5c162196141, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Sep 01 11:55:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244087, encodeId=166f124408e27, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Tue Aug 30 23:55:59 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-10-16 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1861513, encodeId=b6ab186151330, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Jan 17 14:55:59 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831645, encodeId=97b4183164555, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Oct 16 19:55:59 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621961, encodeId=2c5c162196141, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Sep 01 11:55:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244087, encodeId=166f124408e27, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Tue Aug 30 23:55:59 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1861513, encodeId=b6ab186151330, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Tue Jan 17 14:55:59 CST 2023, time=2023-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1831645, encodeId=97b4183164555, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sun Oct 16 19:55:59 CST 2022, time=2022-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621961, encodeId=2c5c162196141, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Thu Sep 01 11:55:59 CST 2022, time=2022-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1244087, encodeId=166f124408e27, content=lancet上果然牛,感谢梅斯更新及时, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=younei, createdTime=Tue Aug 30 23:55:59 CST 2022, time=2022-08-30, status=1, ipAttribution=)]
    2022-08-30 younei

    lancet上果然牛,感谢梅斯更新及时

    0

相关资讯

Eur Radiol: 如何在CT图像上避免漏诊外伤患者的肋骨骨折?

肋骨骨折是钝性胸部外伤中最常见的创伤形式,发生于约50%的患者。诊断肋骨骨折的常规影像学检查是胸部X线平片。但是,这种方式的灵敏度较低,仅为15%。

Neurology:扩大血管周围间隙内的豆纹动脉夹层

血肿位于10年前偶然发现的扩大的血管周围间隙(PVS)内。怀疑PVS内的豆纹动脉创伤性夹层是缺血性和出血事件的原因。

JNNP:高危痴呆症中年人的创伤和抑郁症状:预防性痴呆研究

目的:阿尔茨海默病(AD)和抑郁障碍曾经被认为是没有关系的。但是现在抑郁症被认为与AD密切相关。晚期抑郁症会使未来痴呆的风险增加1.65倍,同时也增加了从轻度认知障碍发展到痴呆的风险。这两种病理学的潜

阻挡钉(Poller钉)怎么打?

干骺端长斜形骨折采用髓内钉固定的难点之一为骨折对线的恢复,由于骨折暴力因素或骨折周围肌肉的牵拉,断端间通常存在侧方移位趋势,在髓内钉置入时如何纠正骨折断端对位对线是临床较常见问题。

Crit Care:血小板输注对创伤患者结局的影响

尽管入院时的血小板计数主要在正常范围内,但它与创伤严重程度和凝血功能障碍相关,并且可以预测出血强度和患者结局。6小时内的早期血小板输注与严重出血患者死亡率的降低相关。

Brit J Surg:创伤后长期使用阿片类药物的危险因素与患者结局

由此可见,创伤与长期使用阿片类药物有关。这些患者在创伤后6-18个月内仍有较高的死亡风险。

Baidu
map
Baidu
map
Baidu
map